| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
|
Medicine details |
|
| Medicine name | neratinib (Nerlynx®) |
| Formulation | 40 mg film-coated tablet |
| Reference number | 1063 |
| Indication | Extended adjuvant treatment of adult patients with early‑stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy |
| Company | Puma Biotechnology, Inc. |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 06/02/2019 |
| NICE guidance | |